Pomalidomide-C7-COOH is primarily utilized in the development of targeted cancer therapies, particularly in the treatment of multiple myeloma. It serves as a key intermediate in the synthesis of antibody-drug conjugates (ADCs), where it is conjugated to monoclonal antibodies to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. This compound is also employed in research to study the mechanisms of immunomodulatory drugs and their effects on tumor microenvironments. Additionally, it plays a role in the design of prodrugs, enhancing the bioavailability and therapeutic efficacy of anticancer agents. Its applications extend to drug discovery, where it is used to develop novel compounds with improved pharmacological properties.